Seroatlas · Human Serome Atlas

BTNL9

Butyrophilin-like protein 9

Also known as: BTN8, BTNL9_HUMAN, FLJ32535

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UXG8
Gene: BTNL9
Ensembl: ENSG00000165810
Chromosome: 5
Canonical length: 535 aa
Protein class: Predicted membrane proteins
Subcellular location: Nuclear membrane,Vesicles

OverviewNCBI Gene

Predicted to enable signaling receptor binding activity. Predicted to be involved in T cell receptor signaling pathway and regulation of cytokine production. Predicted to be located in plasma membrane. Predicted to be active in external side of plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

535 residues, UniProt reviewed canonical sequence.

>Q6UXG8|BTNL9
     1  MVDLSVSPDS LKPVSLTSSL VFLMHLLLLQ PGEPSSEVKV LGPEYPILAL VGEEVEFPCH
    61  LWPQLDAQQM EIRWFRSQTF NVVHLYQEQQ ELPGRQMPAF RNRTKLVKDD IAYGSVVLQL
   121  HSIIPSDKGT YGCRFHSDNF SGEALWELEV AGLGSDPHLS LEGFKEGGIQ LRLRSSGWYP
   181  KPKVQWRDHQ GQCLPPEFEA IVWDAQDLFS LETSVVVRAG ALSNVSVSIQ NLLLSQKKEL
   241  VVQIADVFVP GASAWKSAFV ATLPLLLVLA ALALGVLRKQ RRSREKLRKQ AEKRQEKLTA
   301  ELEKLQTELD WRRAEGQAEW RAAQKYAVDV TLDPASAHPS LEVSEDGKSV SSRGAPPGPA
   361  PGHPQRFSEQ TCALSLERFS AGRHYWEVHV GRRSRWFLGA CLAAVPRAGP ARLSPAAGYW
   421  VLGLWNGCEY FVLAPHRVAL TLRVPPRRLG VFLDYEAGEL SFFNVSDGSH IFTFHDTFSG
   481  ALCAYFRPRA HDGGEHPDPL TICPLPVRGT GVPEENDSDT WLQPYEPADP ALDWW

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BTNL9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 236 nTPM

Expression across tissuesHPA

Tissue

adipose tissue: 236 nTPM
breast: 197 nTPM
heart muscle: 104 nTPM
lung: 98 nTPM
spleen: 56 nTPM
skeletal muscle: 44 nTPM

Single-cell type

vascular endothelial cells: 361 nCPM
pericytes: 82 nCPM
fallopian secretory cells: 68 nCPM
adipocytes: 40 nCPM
renal collecting duct intercalated cells: 37 nCPM
brain excitatory neurons: 35 nCPM

Immune cell

memory B-cell: 0.9 nTPM
naive B-cell: 0.7 nTPM
basophil: 0.2 nTPM
neutrophil: 0.2 nTPM
eosinophil: 0.1 nTPM
classical monocyte: 0 nTPM

Brain region

thalamus: 56 nTPM
pons: 31 nTPM
hippocampal formation: 29 nTPM
medulla oblongata: 24 nTPM
amygdala: 24 nTPM
cerebral cortex: 17 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.35
gnomAD pLI: 0
gnomAD missense Z: -0.55
DepMap mean gene effect: 0.08
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

signaling receptor binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BTNL9 as an antibody target. Whether an autoantibody or antibody against BTNL9 could matter depends on whether native BTNL9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BTNL9 is annotated at the cell surface, where native BTNL9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BTNL9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...